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Engineering and manufacturing of pharmaceutical co-crystals: A 
review on solvent-free manufacturing technologies 
S. A. Ross,a D. A. Lamproubc* and D. Douroumisa* 
Design and synthesis of pharmaceutical cocrystals have received great interest in the recent years. Cocrystallization of 
drug substances offer a tremendous opportunity for the development of new drug products with superior physical and 
pharmacological properties such as solubility, stability, hydroscopicity, dissolution rates and bioavailability. It is now 
ƉŽƐƐŝďůĞƚŽĞŶŐŝŶĞĞƌĂŶĚĚĞǀĞůŽƉĐŽĐƌǇƐƚĂůƐǀŝĂ ?ŐƌĞĞŶĐŚĞŵŝƐƚƌǇ ?ĂŶĚĞŶǀŝƌŽŶŵĞŶƚĂůĨƌŝĞŶĚůǇĂƉƉƌŽĂĐŚĞƐƐƵĐŚĂƐƐŽůŝĚ-
state synthesis in the absence of organic solvents. In addition, significant efforts are placed on computational screening, 
cocrystal manufacturing in a continuous manner and real-time monitoring for quality purposes by using various analytical 
tools. Pharmaceutical cocrystals are not fully exploited yet and there is a lot of ground to cover before they can be 
successfully utilized as medical products. 
Introduction 
Though the term cocrystal did not exist at the time, the first known 
to be created was reported in 1844 by the German chemist Friedrich 
Wöhler 1; where formed a cocrystal of Quinone and Hydroquinone. 
Several other cocrystals were reported over the next century, 
however the phrase was first coined by M.T. Etter et al 2, 3 in 1992. 
Throughout the 1900s, numerus cocrystals have been discovered 
and as knowledge of intermolecular interactions has increased, it is 
possible to design cocrystals to achieve the desired physicochemical 
and biological properties of an Active Pharmaceutical Ingredients 
(API). The last decade has seen a renewed interest in cocrystals 
research, mostly due to increased interest in the pharmaceutical 
industry, due to the potential to enhance the physiochemical 
properties of known API which can be potentially patented and 
developed into a new marketable drug 3-5. 
 There is currently some debate as to the definition of a cocrystal. 
Most publications agree that a cocrystal is a crystalline structure, 
comprised of at least two components 6-8. Under the US Food and 
Drug Administration (FDA) latest guidelines, cocrystals are defined as 
 “ƌǇƐƚĂůůŝŶĞŵĂƚĞƌŝĂůƐĐŽŵƉŽƐĞĚŽĨƚǁŽŽƌŵŽƌĞŵŽůĞĐƵůĞƐǁŝƚŚŝŶƚŚĞ
ƐĂŵĞĐƌǇƐƚĂůůĂƚƚŝĐĞ ?9. However, a number of publications argued to 
use a more restrictive definition where the components are solid in 
their pure forms under ambient conditions and where these 
components co-exist as a stoichiometric ratio of a target molecule 
and a neutral molecule or coformer 10, 11. However, others have 
argued that the restriction based on the ambient conditions is 
arbitrary 8. A recent perspective12, authored by 46 scientists aimed 
to come to a consensus on the exact definition of a cocrystal. The 
perspective states that:  ?ŽĐƌǇƐƚĂůƐ ĂƌĞ ƐŽůŝĚƐ ƚŚĂƚ ĂƌĞ ĐƌǇƐƚĂůůŝŶĞ
single phase materials composed of two or more different molecular 
and/or ionic compounds generally in a stoichiometric ratio which are 
ŶĞŝƚŚĞƌ ƐŽůǀĂƚĞƐŶŽƌ ƐŝŵƉůĞ ƐĂůƚƐ ?12.  It is important to note that a 
cocrystal is different in definition from a pharmaceutical cocrystal; 
the difference being that in a pharmaceutical cocrystal one of the 
components is an API and the other a coformer 13. Because cocrystals 
are formed with their molecular components in a stoichiometric ratio 
the intermolecular reactions between the API and the coformer 
interact via non-covalent, such as ionic interactions, hydrogen 
bonding and Van der Waals interactions taken place 14.  
Cocrystals are bi-molecular entities, which allow the formation of 
diverse crystal forms when compared to the component molecules. 
The diverse crystal structures, which stem from the intermolecular 
interactions of the cocrystal, enhanced the physical and chemical 
performance of the API which are far different from that of the 
individual compound. However, the key advantage that cocrystals 
hold is that while the API will benefit from physiochemical 
enhancements, the pharmacological properties will not be altered. 
The result is a largely bioavailable product 15. The effect on the 
physiochemical properties of the API is dependent on the available 
coformer. With this in mind, it is possible to maximise an APIs 
bioavailability by careful selection of the coformer. This is necessary 
to achieve the drugs intended properties and to avoid any potential 
toxic effects, so a thorough screening process is needed to select the 
right coformer 16, 17. It is important that the coformer is no known to 
have any toxic effects, or for that matter, any adverse effects which 
could affect the properties of the API. For example, it has been 
shown that using benzoic acid has the potential to increase the 
solubility of AMG 517 when they are cocrystallized, but that does not 
mean it is the case for all APIs 18. For example, when benzoic acid is 
used as a coformer with fluoxetine hydrochloride, the opposite 
occurs and a decrease in solubility will be observed 19. To prevent 
cocrystallizing with a coformer which has the potential to cause toxic 
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effects, the coformer should be included on the US FDA  ?ǀĞƌǇƚŚŝŶŐ
ĚĚĞĚƚŽ&ŽŽĚŝŶƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐ ? ?&h^ ?ůŝƐƚ ?dŚŝƐůŝƐƚĐŽŵƉƌŝƐĞƐ
over 3000 substances that are suitable as food additives, or approved 
as generally regarded as safe (GRAS) 20.  Factors effecting the 
physiochemical properties of the cocrystal are the synthetic 
procedure employed, the properties of the API and coformer and the 
nature of the molecular interactions between the two. These 
parameters can be modified to ŝŵƉƌŽǀĞƚŚĞĚƌƵŐ ?ƐƉƌŽƉĞƌƚŝĞƐ ?These 
properties include the solubility, dissolution, chemical stability, 
compressibility, hygroscopicity and melting point 21. These factors all 




Due to the differences in molecular structure and the nature of the 
interaction between API and coformer, cocrystals will display 
different physiochemical properties. The cocrystals melting point is a 
prime example of how the selection of a coformer can engineer a 
drug with desirable properties. Studies have shown that is possible 
to raise or lower the melting point of API by selecting a coformer with 
a melting point greater or lesser of that of the APIs, for example, 
Stanton and Bak 18 investigated ten 1:1 cocrystals of AMG 517 with 
different coformers. The cocrystals all displayed a melting point 
between the API and coformer. They determined a correlation 
coefficient of 0.7849, which means 78 % of the variability of the 
cocrystals melting point, corresponds with the variability of the 
ĐŽĨŽƌŵĞƌƐ ? ŵĞůƚŝŶŐ ƉŽŝŶƚ ? dŚŝƐ ƐƵŐŐĞƐƚƐ ŝƚ ŝƐ ƉŽƐƐŝďůĞƚŽ ƚƵŶĞ ƚŚĞ
melting point of the cocrystal through the selection of coformer. For 
example, if one wanted to synthesize a higher melting cocrystal, then 
a higher melting cocrystal should be selected and vice versa if a 
cocrystal with a lower melting point is required 21. The melting point 
is important during drug design and the fact it can be modified is 
makes cocrystals attractive to the pharmaceutical industry. It has 
been shown that there is a correlation between solubility and 
melting point and that a higher melting point demonstrates the new 
material is thermodynamically stable 22. Lowering the melting point 
of cocrystals can also prove beneficial during pharmaceutical 
processing. For example, when dealing with heat-labile drugs such as 
carbamazepine, processing at high temperatures can cause chemical 
degradation 23. In a 2011 report Rahman et al., 24 selected 
Nicotinamide as a coformer for carbamazepine and was able to 
process solid dispersions at 160 °C using hot-melt extrusion (HME). 
This was far below the 190 °C melting point of the API, demonstrating 
it is possible to lower the melting point of carbamazepine through 
cocrystallization of a coformer with a much lower melting point (126 
°C).  
It is possible to enhance the chemical stability of an API through 
cocrystallization. For example, carbamazepine has been shown to 
undergo chemical degradation after forming a hydrate 25. After 
cocrystallization with a saccharin coformer, the packing arrangement 
in the carbamazepine molecules is altered. As a result, the 
carbamazepine-saccharin cocrystals demonstrated favourable 
stability when compared to the bulk substance 26. 
If a drug has a high hygroscopicity, it is likely that moisture uptake 
from the atmosphere will convert the drug into its hydrate form, 
leading to it displaying unwanted properties. Hydrate formation is 
dependent on the interactions between the API and the solvent in 
the crystals. Through cocrystallization it is possible to replace these 
API-solvent interactions. The reduced availability of unreacted 
hydrogen bonds inhibits hydrate formation in the crystalline lattice 
of cocrystals. This has been demonstrated in studies by Trask et al 27 
where oxalic acid was employed as a coformer for caffeine and 
theophylline to produce cocrystals. Both cocrystals showed no signs 
of hydrate formation over a period of 7 weeks at 98 % relative 
humidity (RH) 28.  
Due to the unique layer structure of cocrystals they have been 
shown to exhibit improved mechanical properties compared to the 
bulk product. This is of specific interest to the pharmaceutical 
manufacturing industry as to improve efficiency; pharmaceutical 
products must have specific compaction properties. Sun and Hou 
found that caffeine-methyl gallate cocrystals display good plasticity 
and improved tabletability, without lamination at high compaction 
force 29. It has been found that by using nicotinamide as a coformer 
for ibuprofen and flurbiprofen, the resulting cocrystals display 
improved compressibility and improved tableting behaviour 30.  
The past two decades has seen a substantial increase in the 
complexity and specificity of pharmaceutical drugs. The increased 
complexity has been accompanied by a decrease in the bioavailability 
of the API 28. For a drug to be effective it must be readily available at 
the target site after administration, as bioavailability describes the 
degree to which a drug can achieve this. Solubility, permeability and 
stability are key factors which affect the bioavailability of 
pharmaceutical products. Approximately 40 to 70 % of drugs 
screened in industrial research have poor water solubility 31. After 
delivery, pharmaceutical drugs must dissolve in the intestinal fluid in 
order to be absorbed into circulation. Poor solubility will limit the 
amount of API that is available for absorption. If the product also has 
poor permeability, then a further decreased amount of API will be 
able to transfer across the human intestinal membrane. Because of 
this the solubility and dissolution of the API is a major concern and 
one of the main challenges to overcome during drug development. 
The solubility must be enhanced whilst maintaining a stable form. 
This objective can be achieved through cocrystallization, which is 
part of the reason it has seen increased interest over the last decade 
12, 32.   
Drugs solubility is determined by the solvation of the components 
and the strength of the crystal lattice. To enhance drug molecules 
solubility, the solvent affinity must be increased and/or can lower the 
lattice energy. Both of these conditions can be met through 
cocrystallization 32.  Arguably the most important parameter which 
influences solubility and/or dissolution is the solubility of the 
coformer, which is the reason that the selection of the coformer is of 
paramount importance when designing drug formulations. Cocrystal 
solubility strongly correlates with the solubility of its coformer 33-35. 
This is due to a decrease in the solvation barrier for a cocrystal to an 
extent which is proportional to that of the pure coformer. Other 
factors such as particle size, dissolution media, and cocrystal 
morphology have a reduced influence in cocrystal solubility 16.  
In a 2009 study Good and Rodriguez-Hornedo 33, set out to 
establish the influence of the API and coformer on the cocrystals 
properties using carbamazepine, caffeine and theophylline and a 
selection of different coformers in order to test the solubility of a 
large number of cocrystals. The results proved that cocrystal 
solubility increases with the solubility of both constituents. The 
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research suggests that selecting a coformer with a solubility 10-fold 
higher than the API will result in a cocrystal with enhanced solubility 
33. Though it is the strength of the lattice (which is primarily 
influenced by the coformer selected) which dictates solubility where 
there is little resistance to solvation. It has been shown that the 
dissolution media plays a great role in the cocrystals overall 
solubility. Solvation has been shown to dictate the aqueous solubility 
of the cocrystal, which is the reason of the selection of coformer it 
should ideally be ŽŶĞƚŚĂƚ ?Ɛable to dissolve in conditions similar to 
the human gastrointestinal tract as to aid the drugs bioavailability. 
This demonstrates that decreasing the solvation barrier is the key to 
increasing cocrystal solubility 36, 37.   
A recent study conducted by Serrano et al 38 demonstrated how the 
cocrystals morphology can determine the properties they exhibit. 
Four different cocrystals structures were formulated with their 
morphology confirmed through scanning electron microscopy (SEM); 
were either large plate-like, large prismatic, small cube-like or 
microsphere cocrystals. It was found that the microsphere cocrystals 
produced by spray drying resulted in much improved compaction 
properties and small cube like cocrystals demonstrated the faster 
dissolution.  
 
Importance in industry 
Though cocrystals have been long since discovered, cocrystallization 
has been a relatively un-researched area until recently. Cocrystal 
research is experiencing ever increasing interest due to their new 
found relevance in the pharmaceutical industry. This is mostly due to 
the fact they present opportunities to edit the composition of matter 
and change the chemical and or physical properties of molecules, 
without the need for covalent modification of the drug molecule 39. 
As previously mentioned, cocrystals ability to enhance bioavailability 
and other properties give them a distinct advantage and for that 
reason the pharmaceutical industry has great incentive to research 
and develop cocrystals. As scientific understanding of the non-
covalent mechanisms which dictate cocrystal properties has 
advanced, researched has increased.  
This is not however the only reason scientific interest in cocrystals 
has increased. Because pharmaceutical cocrystals are structurally 
different to their bulk forms, it is possible to patent cocrystals of 
existing APIs as a new crystal form. In 1995 Eli  ?Lilly 40 patented 
complexes of cephalosporins and carbacephalosporins with 
parabens and various compounds and a cocrystal of sildenafil citrate 
and acetyl salicylic acid with higher solubility in acidic media was 
patented in 2007. If the cocrystal is then found to exhibit enhanced 
clinical advantages, the company can develop the cocrystal as a new 
drug 41, 42. Cocrystals also have the potential advantage of shortening 
the drug development timeline. As the drug development groups are 
working with known API, much will already be known in the areas 
pertaining to drug discovery and toxicology 43. Shorter development 
times equate to less cost, which is appealing to pharmaceutical 
companies. Cocrystals solid-state synthesis techniques can be 
classified as green chemistry as they offer high yield, no solvent use 
and there are few by-products. The continuous mechanisms used to 
form cocrystals also require low energy costs, which is attractive to 
pharmaceutical companies 44, 45.  However, marketed cocrystals 
products are expected to show a moderate growth due to the 
significant experimental efforts and regulatory risks related to their 
approval. In addition, the current industrial perspective considers 
ĐŽĐƌǇƐƚĂůƐ ĂƐ ĂŶ ĂůƚĞƌŶĂƚŝǀĞ ĨŽƌ  “ĚŝĨĨŝĐƵůƚ W/Ɛ ? ƚŚĂƚ ŝƐ ŚĂƌĚ ƚŽ
crystallize or purify 46. A typical example of marketed pharmaceutical 
cocrystals is sildenafil citrate known as Viagra (Pfizer) used to treat 
male erectile dysfunction and pulmonary arterial hypertension 47. 
 
Crystal engineering and Coformer selection 
Crystal engineering is the construction of crystalline solid-state 
structures with desirable properties based on the understanding of 
intermolecular interactions to dictate the arrangement of molecules 
in the crystal structure 48. The concept of crystal engineering was first 
implemented by Schmidt 49 in 1971 and has now become an 
archetype for the synthesis for new compounds. When a compound 
is formed from non-covalent interactions, the molecules in the 
structure are held together by synthons. Hydrogen bonds are often 
utilized in cocrystal design due to their directionality, strength and 
frequency of occurrence in organic molecules. In 1991, Etter 50 
proposed 3 rules for preferred hydrogen bond patterns: all available 
acidic hydrogen molecules will be used in the bonds formation, all 
hydrogen bond accepters will be used when there are available 
hydrogen bond accepters, and the best hydrogen bond donners and 
hydrogen bond accepters will form bonds to one another. It is the 
strength of the hydrogen bonds between the cocrystal formers, 
which govern the formation of synthons, as opposed to the number 
of available groups (Scheme 1). It is possible to predict and rank the 
possibility of synthon formation occurring between different 
functional groups, through utilizing these rules. 
Essentially, synthons are the basic structural units within 
supermolecules, which form through non-covalent bonding and 
consist of molecular fragments and the supramolecular associations 
between them 51. There are two types of supramolecular synthon: 
supramolecular homosynthons, composed of self-complementary 
functional groups and supramolecular heterosynthons composed of 
different but complementary functional groups 52. Supramolecular 
heterosynthons are formed due to the non-covalent bonding 
between different, but complementary functional groups. It is the 
formation of the supramolecular heterosynthon between the API 
facilitates cocrystal formation 53. Because of these rules, it is possible 
to theoretically predict and rank the possibility of synthon formation 
between different functional groups. For example, a commonly 
occurring homosynthon is an amide homodimer forming a cocrystal 
Scheme 1 Hydrogen bonding: a The indomethacin a-form. Two of the 
three symmetrically independent molecules form a carboxylic acid dimer 
synthon and the carboxylic acid group of the third molecule forms an O W
H>O hydrogen bond with the amide carbonyl group of one of these two 
molecules. b The indomethacin g-form. The two molecules form a robust 
acid dimer synthon. c The carbamazepine Wsaccharin (CBZ WSAC) cocrystal 
contains an imide dimer synthon and forms N WH>O hydrogen bonds with 
the saccharin molecule. Reprinted with permission from 116.  
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through C=O··H WN hydrogen bond. Carboxylic acid-pyridine and 
carboxylic Wamide. Are commonly occurring heterosynthons. This 
concept is employed in what is known as the supramolecular 
approach to cocrystal screening, where the Cambridge structural 
database (CSD) is also used to identify appropriate coformers for an 
API 54. 
The CSD is a repository used to store data on molecular crystal 
structures. This is a validated tool to use in cocrystal screening as it 
prioritizes coformers, which can be used with a selective API based 
on whether or not a suitable supramolecular heterosynthon can be 
identified 55. The CSD is well curated and updated with approximately 
50,000 new structures added each year 56.  
Because the physiochemical nature of the coformer effects that of 
the cocrystal, the coformer selection is a vital part of the 
pharmaceutical cocrystal design process. Traditionally, a trial and 
error approach was employed where the selected API would be 
synthesised with an array of pharmaceutically acceptable 
ingredients, however such an approach is expensive and inefficient 
57. Statistical analysis of cocrystal data on the CSD allows for research 
groups to apply virtual screening techniques to find appropriate 
cocrystal forming pairs, so cocrystals can be designed through 
molecular modelling, cutting both research time and experiment 
cost 58. If molecules are able to interact through different, competing 
synthons, then a hierarchy must be established based on what the 
cocrystal is being designed to do. It must be known which synthons 
are formed at the expense of others. Numerous weaker interactions 
limit cocrystal design and using the CSD to identify and overcome any 
factors, beyond synthon forming which influence the failure or 
success of the cocrystal 52. Through analysing the simple atom, bond 
and group counts, hydrogen bond donor and acceptor counts, size 
and shape descriptors, surface area descriptors (with partitioned and 
charge weighted variants), and molecular electrostatic descriptors 
and polarity descriptors of cocrystals found in the CSD, one can far 
more accurately predict the complementary of their cocrystal 
components 59-62. It is possible to filter out any suspicious crystal 
structures, such as duplicates and incomplete structures from the 
CSD by using the Van der streek 63 list for best representatives of each 
unique polymorph, which further simplifying the process. In one 
specific example of this Lemmerer et al. 64 used the CSD to analyse 
the regularly occurring synthons for functional groups present in 2-
chloro-4-nitrobenzoic acid and found that nicotinamide would form 
 W forms hydrogen bonded C(4) chains from the H atom in the anti-
position to the carbonyl O and from the he syn-H to the pyridine N 
to form C(6) chains. Through using molecular modelling calculations 
to examine the in the torsions angles in the crystal structures they 
were able to formulate a new cocrystal between 2-chloro-4-
nitrobenzoic acid and nicotinamide.  
Other methods of virtual screening have been demonstrated in 
literature. Issa et al 65 first attempted to predict the likelihood of 
cocrystal formation by comparing lattice energies of documented 
cocrystals with the sum of the lattice energies of their components. 
This idea was expanded upon by Grecu et al 66, where they developed 
a computational method for identifying API coformer pairs with a 
high chance of successfully forming cocrystals by calculating their 
functional group interactional energies. Using Nalidixic Acid as model 
API 44 of the most promising cocrystals were established from a 
library of 310, only 6 of which were known compounds. The other 38 
where then ranked in order of probability. This was done by utilizing 
surface site interaction points (SSIP) which are calculated from the 
molecular electrostatic potential surface of the isolated molecule in 
the gas phase. The molecules interaction with its environment is then 
expressed via sets of SSIPs, each of which is represented by an 
interaction parameter. This is either positive for a hydrogen bond 
donor site or negative for a hydrogen bond accepter site. From this, 
the energy of interaction of the two SSIPs is presented, without the 
need of prior knowledge of the crystal structure. A Hierarchy 
between interactions can then be established by paring the most 
positive SSIP with the most negative, the second most positive with 
the second most negative and so on. This result indicates the 
potential of visual screening as a major tool in cocrystal development 
66. To further validate this method Grecu et al 54 tested this lattice 
energy screening model against experimentally screened cocrystals, 
in which the virtual cocrystal screen reproduces experimental results 
well, giving further credibility to this approach (Scheme 2). 
Synthon matching is the key theory relied upon during cocrystal 
screening, but there are other factors which can determine the 
success of the cocrystal. One of the drawbacks of the computerized 
supramolecular synthon approach is that one cannot accurately 
predict the in vivo properties of the cocrystals. This is since the 
primary focus of the supramolecular synthon approach is to evaluate 
whether or not a hydrogen bond could exist between API and 
coformer and calculate the bonds strength and not on the 
physiochemical properties exhibited by API and coformer. One 
example for this is that after the synthesis of lamotrigine-
nicotinamide cocrystals it was found that although the nicotinamide 
enhanced the solubility of lamotrigine it also possessed the ability to 
decrease the oral bioavailability 14.  
One such method of experimentally screening for the experimental 
screening of cocrystals is by using thermal analysis. One way to do 
this is by studying the two components phase behaviour using 
Differential scanning calorimetry (DSC). With this method, a physical 
mixture of two potential cocrystal forming components are placed 
inside the DSC and heated beyond their point of eutectics. If 
cocrystallization is possible then an endothermic peak associated 
with the eutectic melting will be observed, immediately followed by 
an exothermic peak which indicates the cocrystallization of the two 
components. Another endothermic point will then be observed at 
the cocrystals melting point. By contrast, if cocrystallization is not 
possible between the two components, then a single endothermic 
peak indicating the eutectic melting is observed 67, 68. It is the 
presence of the exothermic peak and second endothermic peak 
Scheme 2 (a) The chemical structure of nalidixic acid. (b) The DFT MEPS 
(density functional theory - molecular electrostatic potential surface) (red is 
negative and blue is positive). (c) The SSIP (surface site interaction points) 
representation (red is negative and blue is positive, and the size of the sphere 
ŝƐƉƌŽƉŽƌƚŝŽŶĂůƚŽɸŝ ? ?Reprinted with permission from Ref. 124. 
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which indicates cocrystallization is possible. This technique was first 
demonstrated by Lu et al., where DSC was used to screen twenty 
possible cocrystal forming systems. Sixteen cocrystals were formed, 
including nine previously undiscovered, demonstrating the DSCs 
potential for cocrystal screening 69. This method of experimental 
screening is popular as it does not require the time consuming work 
of solubility determination and is considered green technology due 
to the absent of organic solvents 70. However, in a 2014 comparative 
study by Manin et al., 71 DSC was found to be the least effected 
thermal screening method giving many ambiguous results. For this 
reason, DSC is usually combined with hot stage microscopy (HSM) in 
order to allow the observation of cocrystal formation directly. The 
utilization of HSM is desirable as it allows the interpretation of 
ambiguous results 72. It is also possible to combine DSC with Fourier-
transform infrared spectroscopy (FT-IR) to establish the correlation 
between the thermal response and the structural changes of the 
sample 73.  
Another method of thermal screening for cocrystals is by 
measuring the components saturation temperatures. First 
demonstrated by Joop ter Horst 10, this is accomplished by measuring 
situation temperature at a composition which correlates with the 
saturation, with respect to both of the cocrystal constituents at a 
reference temperature. If the saturation temperature is more than 
10 ȗŚŝŐŚĞƌƚŚĂŶƚŚĞƌĞĨĞƌĞŶĐĞ ?ŝƚŝŶĚŝĐĂƚĞƐƚŚĂƚĐocrystallization has 
occurred. Manin et al 71 found the situation temperature method to 
be the most effective in cocrystal screening, compared to both DSC 
and HSM. However, it is also the most time consuming and requires 
the use of a solvent.  
As previously mentioned HSM can be utilized in the screening of 
cocrystals by applying what is known as the kofler contact method.  
Using this method, the cocrystal constituent with the higher melting 
point, be it the API or coformer is melted and then allowed to solidify. 
The constituent with the lower melting point is also melted and 
placed in a contact zone with the other constituent. The solidified 
constituent is then dissolved in the liquid constituent, producing a 
mixing zone where the sample is quenched and then recrystallized. 
On either side of the mixing zone is the pure component of both of 
the cocrystal formers. The sample is heated once more until it 
reaches its melting point, under the HSM equipped with a polarizer. 
One can then view the newly formed cocrystal, beside the two pure 
components in the mixing zone. The cocrystal phase will retain 
birefringence and be distinguishable from the eutectic phase and the 
pure components, giving clear indication to whether or not 
cocrystallization was successful 64, 72, 73. 
 
Another approach to experimental screening of cocrystals is by co-
grinding. This approach involves mechanically grinding the cocrystal 
components together and observing whether cocrystals have formed 
through characterization techniques. Traditionally this can be 
achieved through either solid or liquid assisted screening methods. 
Liquid assisted screening have been proven to be most popular, with 
Ainouz et al 74 using this method along with computational prediction 
to assess the suitability of coformers with an API. Solid grinding can 
be viewed as preferable as there is no solubility limit influencing the 
system and there is no solvent present to disturb the interaction 
between the API and coformer. These methods however are 
incredibly time consuming. In an attempt to combat this, Yamamoto 
et al ĚĞǀŝƐĞĚĂ “ĐŽĐƌǇƐƚĂůĐŽĐŬƚĂŝůŵĞƚŚŽĚ ?ǁŚĞƌĞĨŽƵƌĐŽĨŽƌŵĞƌƐŽĨ
identical moieties were ground simultaneously with the API in a ball 
mill, and characterisation carried out on the results in order to 
observe whether any of the coformers had reacted favourably with 
the API to produce cocrystals; this method was found to decrease the 
workload by 50 % 75. 
Another theoretical technique, which has been utilized in coformer 
selection, is the Hanson solubility parameter (HSP). Predicting the 
miscibility of the cocrystal constituents by using the solubility 
parameters can indicate the likelihood of cocrystals forming. At a 
molecular level, cocrystals are miscible systems. Therefore, it is 
possible to predict the prospect of cocrystal formation based on the 
miscibility of the components in the solid state. If the difference 
between the solubility parameters of two entities is less than seven, 
then they are miscible and if the coformer is miscible with the API, 
cocrystallization should occur 76, 77. This concept was investigated by 
Mohammed et al 78, where the miscibility for indomethacin and 33 
coformers were calculated using HSP. From this, all except one of 
drug-coformers which were predicted to be miscible were 
experimentally confirmed as miscible. It was also found that all the 
indomethacin-coformer pairs that formed cocrystals were miscible. 
Although, one of the coformers that formed cocrystals demonstrated 
miscibility with the API, not all drug/coformer systems formed 
cocrystals. This can be due to lack of hydrogen bonding, preferred 
packing patterns and molecular shape and size, which this method 
does not allow for 78, 79. 
 
By-products in cocrystal screening 
Cocrystallization has proven not to be a predictable process. For 
example, many API and coformer pairs, chosen based on 
potential synthon formation do not produce cocrystals. Often 
unwanted solid forms will be present after the cocrystallization 
experiment such as polymorphs, solvates, hydrates, eutectics, 
solid solutions or physical mixture (Scheme 3). The discovery of 
physical mixture in the batch is an indication that the 
cocrystallization has failed, as the bulk products have not reacted 
as desired. Crystalline solid solutions are single phase, 
multicomponent solids formed between isomorphous or 
isostructural materials, meaning that solid solutions form when 
both the API and coformer have the same type and positioning of 
Scheme 3 Flow chart of potential outcomes of cocrystallization. Reproduced 
from Ref. 84 with permission from The Royal Society of Chemistry. 
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functional groups and the same unit cell dimensions. Thus, solid 
solutions retain the lattice structure of the main component. The 
consequence of this is that the pharmaceutical properties of the 
API are not enhanced 80. Eutectics are also multicomponent 
crystalline solids, except they are formed from non-isomorphous 
materials. This means there are size and shape differences 
between the two components and the hetromolecular 
interactions between the two components are weaker than that 
of a cocrystal, resulting in a lower melting point. In 
cocrystallization, the hetromolecular interactions will overcome 
the size and shape differences, resulting in a distinct crystal 
packing ƚŚĂŶ ƚŚĂƚ ŽĨ ƚŚĞ ƉƵƌĞ ĐŽŵƉŽŶĞŶƚ ?Ɛ ? /Ŷcontrast, the 
packing arrangement of solid solutions and eutectics are similar 
to the original constituents 81.  
One of the major downsides to liquid assisted grinding 
techniques for cocrystal production, which will be covered later 
in the review, is the potential for an unwanted solvate to form 
between the solvent and either the API or coformer. In one 
example, during a recent study by Madusanka et al 82 to Identify 
polymorphic forms of caffeine and anthranilic acid cocrystals via 
liquid assisted grinding, five different cocrystal solvates were 
formed with each of the solvents used.  
Another potential unwanted outcome from cocrystal screening 
is hydrate formation. It is common for API to form a hydrate with 
water molecules due to their small size and multi-directional 
hydrogen bonding abilities 83. In addition to altering the 
physiochemical properties of the desired product, the water 
molecules can escape the crystal lattice of the hydrate. This can 
occur at higher temperatures and at lower humidities, meaning 
hydrates are quite unstable. The physiochemical properties of the 
dehydrated form will differ from that of the hydrated form. 
Despite this cocrystal, hydrates are still an area of interest due to 
their resistance to high humidities, which can cause degradation 
in dehydrated forms. Karki et al demonstrated two techniques to 
screen for potential hydrates in cocrystallization; Liquid assisted 
grinding, using water as the solvent and solid state grinding with 
the hydrated form of the constituents. This study also 
demonstrated how different API are more susceptible to hydrate 
formation. The use of the hydrated form of theophylline, steered 
the reaction towards the formation of cocrystal hydrates, but this 
was not the case with hydrated caffeine, which formed cocrystals 
121.  
It is also possible for different polymorphs to form during the 
cocrystallization process. Polymorphism is the ability of a 
substance to exist in two or more crystalline forms, with different 
crystal lattice arrangements. Due to the differences in crystal 
lattice structure, different polymorphs present different 
physiochemical substances. Although they may still be a cocrystal, 
if one is screening for cocrystals, which display a certain beneficial 
property, obtaining a polymorph of the desired cocrystal, with 
different properties, can be seen as a setback. Therefore, 
screening for polymorphs of cocrystals is beneficial 84.  In one 
example Eddleston et al 85 obtained three anhydrous polymorphs, 
a monohydrate and a Dimethyl sulfoxide (DMSO) solvate from the 
screening of phenazine and mesaconic acid cocrystals. The study 
concluded that multi-technique approaches were necessary 
when screening for polymorphs in order to isolate the crystal 
forms.  
 
Hot melt extrusion  
Hot melt extrusion (HME) is a novel technique that is gaining traction 
as a mechanism of producing pharmaceutical cocrystals. The 
technique was adapted from the rubber, plastics and food industries 
and is now seeing increasing use in the pharmaceutical industry 86. 
The technique was first developed as a means of manufacturing lead 
pipes in the 18th century, though since then the process has been 
used in the production of plastic bags, pipes, pasta and palletised 
veterinary foods 87, 88. So far, the primary applications of HME in the 
pharmaceutical industry include the production of solid dispersions 
using polymer or lip materials with the goal of modifying the 
properties of drug release 89. Taste masking of bitter APIs 90 and 
increasing the solubility, dissolution and overall bioavailability of 
poorly water-soluble drugs 91. HME has thus proved a versatile and 
adaptable process which is now accepted as a means of 
pharmaceutical synthesis due to the number of applications having 
been developed through HME processing, which includes pellets, 
tablets, granules, topical or buccal films, implants and recently the 
feasibility of combining HME with 3D printing technology to produce 
tablets has also been explored 92, 93. Another key benefit in HMEs 
ĨĂǀŽƵƌŝƐƚŚĂƚŝƚŵĞĞƚƐƚŚĞĐƌŝƚĞƌŝĂŽĨƚŚĞh^& ?ƐƉƌŽĐĞƐƐĂŶĂůǇƚŝĐĂů
technology (PAT) scheme for designing, analysing and controlling the 
pharmaceutical manufacturing process via quality control 
measurements during active extrusion processing 94. An example of 
drug formulations, developed by HME which have been awarded 
FDA approval include Rezulin, Kaletra and Norvir 95. 
The HME process involves feeding raw materials through a barrel 
containing one or more rotary screws towards a die under controlled 
conditions. Immense friction takes place between the screw and 
barrel at high temperatures which provides good mixing of the raw 
materials, reducing particle size, thus creating cocrystals 96. The 
instrument is principally divided into extruder, auxiliary equipment 
for extruder, downstream processing equipment and monitoring 
tools 97. The temperature of each zone in the barrel is accurately 
controlled by a fixed thermostat and the screw is rotated using 
energy supplied by a motor unit. A die is attached to one end of the 
extruder to mould the processed material(s) into the desired shape.   
One of the other key advantages of HME is that it is relatively 
simple to scale-up production to an industrial scale. The geometric 
similarities between mid-size and large scale HMEs enable rapid 
process scale-up without compromising product quality. Another 
advantage is that HME is a continuous process, which means it is 
more economical and reduces the number of processing steps when 
compared to other techniques, such as ball milling, making it more 
efficient as well 98, 99. Because it is a continuous mechanism, the user 
is easily able to redesign the process to increase throughput and 
maintain acceptable quality at the same scale. The two most 
common variables during scale-up are barrel temperature and screw 
speed. Typically, as the batch size is increased the temperature must 
also increase. This is done to allow the increased product between 
the screws and the barrel wall to absorb the heat (Scheme 4). If 
temperature is not increased a percentage of the product may not 
be sufficiently heated and cocrystals will not form, resulting in a 
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batch of poor purity.  Screw speed must also be increased with the 
feed rate, otherwise the extruder will clog 99, 100.  
Another key advantage is that real-time control, analysis and 
design optimization can be achieved using Process analytical tools 
(PAT) during the extrusion process. The purpose of this is to be able 
to assess the quality of the products by measuring their properties 
during the process. By using PAT during extrusion, it is possible to 
adjust the experiment parameters to improve the products quality 
hid-extrusion. In-line reflectance near infrared spectroscopy (NIR) is 
one analytical techniques commonly employed as PAT tools, with the 
purpose of understanding drug interactions and optimizing the 
process mid extrusion 101, 102. Mordiya et al 91 demonstrated the first 
instance of PAT monitoring in HME where real time NIR monitoring 
was implemented during the extrusion of carbamazepine-saccharin 
cocrystals via extrusion. A fiber-optic NIR probe was fitted at three 
different zones along the extruder barrel (one at each mixing zone) 
in order to study the cocrystals formation in the extruder. It was 
found that cocrystallization of the two components starts in the first 
mixing zone due to the appearance of a cocrystal peak, which 
increases in size as the extrudate moves through the extruder barrel. 
This shows that cocrystals are formed gradually due to increased 
mixing capacity across the mixing zones. Mordiya et al 103 in the 
production of carbamazepine-trans-cinnamic acid cocrystals also 
utilized NIR as a PAT tools for cocrystallization via HME. Once again, 
the NIR probe was fitted at the 3 different mixing zones to monitor 
the cocrystallization process across the barrel. On this occasion, 
cocrystals did not first form until the second mixing zone and then 
continues to form gradually, indicating trans-cinnamic acid does not 
form hydrogen bonds with carbamazepine as readily as Nicotinamide 
(Scheme 5). This indicates that high intensity mixing has a significant 
effect on the quality of cocrystals, likely due to the breakage of solid 
domains, resulting in increased hydrogen bonding. This also proves 
NIRs capacity as an in-line, non-invasive PAT tool for cocrystallization 
via HME. As of yet no studies detailing the user of Raman 
spectroscopy or other PAT techniques for cocrystallization via HME 
have been reported.  
 There are two main types of extruder commonly available on the 
market: single screw (SSE) and twin-screw (TSE). SSE consists of a 
single screw contained within a spiral shaped barrel. The screws 
diameter increases along the length of the extruder shaft. The SSE is 
considered the simpler more cost effective potion and there are less 
processing parameters available to this option, such as less possible 
screw configurations and thus reduced mixing capabilities. TSE is 
built much the same as SSE with the primary difference being that of 
an extra screw. The two screws are placed parallel to one another in 
separate chambers within the same barrel. There is greater industrial 
interest in TSE due to the fact it provides greater mixing capabilities, 
high throughput and reduced residence time compared to the SSE. 
The screws can be set to either co-rotate (both screws rotate 
identically) or to counter rotate (screws rotate in opposite directions) 
104, 105.  
 
Hot melt extrusion in pharmaceutical cocrystal 
production 
The first instance of cocrystallization via HME was reported by 
Medina, et al 106. Using a model drug AMG 517 and caffeine, they 
demonstrated that the TSE can provide suitable surface contact 
between the cocrystal components, due to the highly efficient mixing 
and close material packing, to produce cocrystals without using 
solvents. This research was expanded upon by Dhumal et al 107, who 
explored the effects of different processing parameters of HME in 
the manufacture of agglomerated cocrystals of ibuprofen and 
nicotinamide. They achieved this by employing a quality based 
design approach, by extruding a 1:1 molar ratio of ibuprofen and 
nicotinamide at variable screw speeds, temperature profiles and 
with different screw configurations. It was found that the barrel 
temperature must be above the eutectic point of the physical 
mixture for cocrystallization to occur and demonstrated the extent 
of how the processing parameters affected the purity of the 
cocrystals. Screw configuration was found to have the most 
significant effect on the cocrystallization, with the highest sheer 
configuration producing the purer cocrystals. 
Scheme 4 Photographs of screw elements (a-c) used in various 
configurations (reprinted with permission from Ref. 98) and a typical twin 
 W screw configuration (Reproduced from Ref. 103 with permission from 
The Royal Society of Chemistry). 
Scheme 5 Second derivative of in-line NIR spectra in the mixing zones 
(A, B, and C) of extruded cocrystals in a twin  W screw extruder and the 
physical mixture. Reproduced from Ref. 103 with permission from The 
Royal Society of Chemistry. 
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In 2011, Daurio et al 108, attempted to further demonstrate the 
potential of HME suitable mechanism for manufacturing cocrystals 
on an industrial scale. Arguing that TSE is easily scalable and highly 
efficient way to produce cocrystals, due to the fact the process is 
continuous, they set out to demonstrate this using four model 
cocrystals: caffeine-oxalic acid, nicotinamide-trans cinnamic acid, 
carbamazepine-saccharin and theophylline-citric acid. These 
cocrystals were selected since they had been extensively studied in 
literature and could be easily compared with other cocrystallization 
methods. These results indicated that HME was successful in 
producing high purity batches for all four cocrystals tested.  
Daurio et al 108, was also able to observe the effects of HMEs 
extrusion parameters on the overall conversion of the cocrystal 
batch. When extruding the Caffeine-Oxalic acid cocrystals at the 
same temperature with different screw designs, it was found that 
the design, which allowed for greater mixing provided a higher 
conversion from the bulk products to the cocrystal. Similarly, the 
effect of residence time was demonstrated where X-Ray Powder 
Diffraction (XRPD) data indicated incomplete conversion to 
cocrystals that were extruded at higher screw speeds. When the 
Caffeine-Oxalic acid cocrystals analysed, temperature was the only 
variable parameter with little mixing taking place showed poor 
conversion rates, thus indicating this particular cocrystal to be more 
dependent on residence time and screw configuration. This is in 
stark contrast to the nicotinamide-trans cinnamic acid cocrystal, 
where the extent of cocrystallization, seemed to be primarily 
dependent on temperature. The results for the carbamazepine-
saccharin and theophylline-citric acid were also shown to increase in 
purity as the processing parameters were optimized. Using the 
carbamazepine-saccharin cocrystals as an example, the total 
processing time to produce cocrystals through HME was recorded 
between 2-5 min. In contrast, the ball milling mechanism to produce 
cocrystals has a reported residence time of over 30 min 108, 109.   
To demonstrate the effectiveness in improving the solubility of 
poorly water soluble drugs using HME, Moradiya et al 91, synthesised 
carbamazepine-saccharin cocrystals using both a SSE and TSE. 
Theoretically the TSE would provide better mixing over the SSE. DSC 
results showed far broader peaks for the cocrystals created using the 
SSE in comparison to the cocrystals produced via TSE, indicating a 
reduced purity/less conversion. The dissolution profile showed that 
the carbamazepine-saccharin cocrystals produced via TSE dissolved 
in water faster than those produced via SSE.  This suggests that 
improved mixing is essential to the conversion rate of cocrystals and 
is a key parameter in enhancing the solubility of the cocrystal. It is 
also worth noting that the batches produced at a higher temperature 
presented a quicker dissolution time, demonstrating the extrusion 
temperatures effect on cocrystal solubility. In another example, 
carbamazepine-trans-cinnamic acid cocrystals were extruded by 
both SSE and TSE. DSC and XRPD results showed less crystallinity for 
the cocrystals produced via SSE when compared to those produced 
by TSE. Again, dissolution studies showed that TSE processing 
produced cocrystals with a faster dissolution rate when compared to 
those produced by SSE, demonstrating the effect of increased mixing 
on cocrystal solubility 95, 110 (Scheme 6). 
 Hot-melt extrusion techniques have been demonstrated to be 
advantageous when working with heat labile drugs. When exposed 
to high temperature, a number of drugs begin to thermally degrade. 
Liu et al 111, combined carbamazepine, a heat sensitive API, with 
nicotinamide to form cocrystals to act as a model drug to process 
using HME technology, with the aim of demonstrating 
cocrystallization as a useful strategy to avoid thermal degradation 
during HME. This cocrystal was co-extruded alongside polymers; 
PVP/VA, Soluplus and hydroxypropyl methylcellulose (HSPM). The 
aim of this was to assess the feasibility of cocrystalizing 
carbamazepine to make it more thermodynamically stable during the 
HME process, while being co-extruded with a polymer. The melting 
point of carbamazepine-nicotinamide cocrystals is 160° which is 
significantly lower than melting point of bulk carbamazepine. The 
results showed that it is possible to successfully prepare amorphous 
carbamazepine-nicotinamide-polymer solid dispositions while 
extruding at a temperature far below that of the bulk substances, 
thus preventing heat damage. Nicotinamides great solubility also 
leads to a more soluble cocrystal, thus indicating greater 
bioavailability 112.  
 Another study by Boksa et al. 113, attempted to further improve 
the solubility of carbamazepine-nicotinamide cocrystals through 
adding the polymer Soluplus. This was done through a technique 
dubbed; matrix assisted cocrystallization, where co-processing the 
API and coformer in the presence of a matrix. In this case the 
cocrystal products and Soluplus matrix was co-extruded at an 80:20 
(w/w) ratio. The matrix assisted cocrystal was found to dissolve 
faster than the reference cocrystal, indicating that coextruding offers 
significant solubility benefits.   
In a 2014 study, Daurio et al 114 demonstrated HMEs potential as a 
viable production process for the scale-up of production of 
cocrystals. By employing AMG 517 Wsorbic acid cocrystals as a model 
drug, the extrusion parameters which effect the purity of cocrystals 
were investigated (e.g. temperature, feed rate, residence time, 
screw configuration). The extruded cocrystals were then compared 
with solution grown cocrystals. The results suggested that, contrary 
Scheme 6 Intrinsic dissolution profile of Carbamazepine (a) and 
Carbamazepine -  Nicotinamide cocrystals (b) in different media (Reprinted 
with permission from Ref. 24) and dissolution profiles (0.1 N HCl, pH 1.2) 
of Carbamazepine  W Saccharin prototype (MeOH, EtOH solvents), CBZ-SCH 
cocrystals processed with twin  W screw extrusion at 5rpm and 10rpm 
respectively (reprinted with permission from Ref. 91). 
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to previous literature, the eutectic formation did not mediate 
cocrystal formation in the extruder. However, temperature was still 
found to be a main parameter in dictating cocrystal conversion, along 
with screw configuration. Feed rate and residence time was 
discovered to exert a moderate influence on cocrystallization. The 
TSE approach was found to exert improved surface area, bulk 
density, and flow properties when compared to the solvent 
cocrystallization methods. This further indicates that HSE is an 
efficient, continuous and easily scalable cocrystal production 
method. Below, alternative solid state mechanisms to synthesise 
cocrystals are described. 
One of the persistent issues presenting a challenge to industrial 
uptake of pharmaceutical cocrystals is that of reproducible 
stoichiometry control. It is possible to produce increase the number 
of cocrystal solid forms by using different stoichiometric ratios. 
However, synthesizing different stoichiometries greatly complicates 
the cocrystallization process in most cases. For example, using 
grinding techniques Trask et al 27 found that it was not possible 
consistently reproduce caffeine-malic acid cocrystals of different 
stoichiometries, without the use of a solvent.  In another instance 
Karki et al 119 attempted to produce cocrystals of different 
stoichiometries using Nicotinamide API and 10 different dicarboxylic 
acid coformers. This was attempted using solution techniques as well 
as solid state, liquid assisted and melt assisted grinding. Results 
indicated that approximately 50 % of cocrystals produced by solution 
techniques, 40 % of cocrystals produced via melt assisted grinding 
and only 25 % of cocrystals produced via solid state and liquid 
assisted grinding corresponded to the stoichiometry of the starting 
materials. However, recent research by Kulkarni et al 122 has 
indicated that stoichiometric control over cocrystals is achievable 
through HME. Caffeine/Maleic acid cocrystals as a model drug it was 
demonstrated that by extruding a 2:1 mixture of Caffeine-malic acid, 
it is possible to control the stoichiometry of the final product by 
simply editing the temperature settings. If the 2:1 mixture was 
processed below 104 °C then the formation of a 1:1 cocrystal is 
favoured. If the extrusion temperature exceeds 104 °C then the 1:1 
cocrystal will melt and the components will form a 2:1 stoichiometric 
cocrystal. This indicates that stoichiometric control over cocrystals is 
possible through editing the extrusion parameters of HME, without 
having to edit the initial batch or switch cocrystallization technique. 
This is a major advantage for HME processing as limiting the 
production steps equates to greater efficiency and reduced cost. 
 
Grinding methods for cocrystallization 
There are two commonly utilized mechanisms to synthesize 
cocrystals via grinding. The first is solid state grinding, also known as 
dry grinding, where the cocrystal components are simply ground 
together through manual or mechanical processes. The second is 
liquid assisted grinding, also called solvent drop, where a small 
amount of liquid is added to the mixture to act as a catalyst 115. The 
advantages of solid state grinding to form cocrystals, when 
compared to solution based methods, was presented by Patil et al 
116, who demonstrated that the grinding of mixtures was superior to 
solution growth. This was expanded on by Etter et al 50 who 
demonstrated how the grinding of solids, would cause hydrogen 
bonding of adenine and thymine. These methods were simply carried 
out through manual grinding, which presents the problem to the 
scale up of production, so different mechanical methods must be 
used for efficient cocrystal production. One solid state grinding 
method to form cocrystals is by employing the use of ball milling, 
where particle size reduction is carried out by impact as the cocrystal 
components are loaded into a rotating chamber partially filled with 
steel balls. In one example, Trask et al 117 utilized grinding via ball 
milling to synthesize caffeine cocrystals with several different 
dicarboxylic acids, were 5 different caffeine based cocrystals were 
synthesised.  
Solid state grinding has been used to produce metastable 
polymorphs of cocrystals. Aitipamula et al 118 Used solid state 
grinding techniques to investigate the synthesis of cocrystal 
polymorphs. Through ball milling a 1:1 stoichiometric ratio of 
ethenzamide-Saccharin cocrystal, it was possible to produce two 
polymorphs of the cocrystal. Analysis of the crystal structure 
revealed that both polymorphs were comprised of amide-imide 
supramolecular heterosynthons. These two polymorphs were 
previously unattainable using solvent based cocrystallization 
methods. The study concludes that to capture all possible cocrystal 
polymorphs a diverse range of synthesis techniques including solid 
state grinding. 
Solid state grinding techniques have also been shown to be 
effective in the formulation of cocrystals of stoichiometric variation. 
Stoichiometric variation describes cocrystals composed of the 
identical constituents, which are present in differing ratios.  This was 
demonstrated by Karki et al 119, who argued that solid state grinding 
methods are more efficient than solvent based methods, such as 
solvent evaporation, as the formation of stoichiometric variations 
are easily controllable by modifying the composition of the reaction 
mixture. This was demonstrated by ball milling Nicotinamide as a 
model API with suberic acid, in either 1:1 or 2:1 ratio to form 
nicotinamide-suberic acid cocrystals. The results showed grinding 
techniques allow for greater control of cocrystal composition when 
compared to synthesis techniques requiring liquids. Solid state 
grinding techniques for the synthesis of cocrystals of variable 
stoichiometric ratios had previously been reported by Vishweshwar 
et al 120.  
Liquid assisted grinding can be carried out when there is no sign of 
the formation of a new phase. Liquid assisted grinding will often 
incorporate the use of a small amount of solvent to act as a catalyst 
for the cocrystallization process. To demonstrate the solvents effect, 
Trask el al 117 applied liquid assisted grinding to the synthesis of 
caffeine based cocrystals which were unable to fully crystalize 
through solid state grinding methods. Through the addition of 
solvent of cocrystallization of the caffeine, based drugs took place. 
This form of grinding carries the same inherent issues as solid state 
grinding; however, there is the added issue of solvent disposal with 
liquid assisted grinding along with the potential risks to the 
environment.  
In 2007, Karki et al 121 attempted to compare the solid state and 
liquid assisted grinding techniques for the screening and preparation 
of hydrated cocrystals, using theophylline and Caffeine as a model 
API. In this study, it was found that liquid assisted grinding is less 
sensitive to the form of reactants (hydrate or anhydrite) than the 
neat grinding mechanism, so it was concluded that liquid assisted 
grinding is better suited for cocrystal screening. In another 
comparison between the two methods, Rehder et al 122 used a solid 
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state grinding to process piracetam-citric acid and piracetam-tartaric 
acid using an oscillatory ball mill. In comparison with the solvent drop 
technique, solid-state formulation of the cocrystals was found to be 
slower and displayed reduced crystallinity. This was explained to be 
because of the higher molecular mobility of the API and coformer as 
a result of their partial solubility in the solvent. This contrasts with 
the findings of Viertelhaus et al 123, observed a loss in crystallinity in 
Piracetam-citric acid cocrystals prepared using the same liquid 
assisted grinding method. However, solid state grinding was still 
found to be the slower than liquid assisted, taking up to 10 min to 
complete the process.  
With the objective of investigating the feasibility of forming 
cocrystals through green chemistry methods Basavoju et al 124 
utilized solid state grinding to form indomethacin and saccharin 
cocrystals. Cocrystallization was successfully carried out for both 
solid state and liquid assisted grinding, though with liquid assisted 
grinding the added issue pertaining to the disposal of the solvent was 
encounter. As previously stated can cause potential environmental 
harm, which arguably disqualifies this technique as green chemistry.   
One of the main drawbacks with solid state grinding is that there is 
no heating stage involved in the process. Numerus studies have 
reported the importance of temperature in the cocrystallization 
process, and lacking that component, far more energy is required to 
induce cocrystallization by grinding alone 78, 108, 109-112. One method 
to overcome this is the induction of a solvent as a catalyst to assist 
the extrusion process. There has been a decrease in research into 
solid-state grinding methods, to induce cocrystallization due to 
numerus papers demonstrating liquid assisted grindings superiority 
121-123, 130. In a comparative study, FriVࡊ Fࡊ iFғ  et al 115, attempted to form 
cocrystals of theophylline and caffeine trough solid state grinding, 
liquid assisted grinding and sonic slurry methods. Theophylline-L-
malic cocrystals were the only success using solid state grinding 
methods out of the four possibilities tested. The study also found that 
the Theophylline-L-malic cocrystals produced through solid state 
grinding had an inferior degree of crystallinity than those prepared by 
liquid assisted grinding.  
However, this disqualifies it as green chemistry and adds the extra 
cost of using and disposing of the solvent, especially during large 
scale production. Another drawback for liquid assisted grinding that 
there could potentially be large differences in the solubility of the API 
and coformer rendering this method difficult to perform and in some 
cases impossible 125. There is also the added problem that the 
interactions between the solvent and the API or coformer could 
disturb the interactions between the cocrystal constituents. The 
addition of solvent can lead to the formation of unwanted cocrystal 
solvates 82. For this reason, it can be argued that the addition of 
solvents in cocrystal synthesis are an unnecessary complication as 
well as being a costlier and environmentally unfriendly. Therefore, 
HME is a preferable choice of method, as it combines the heating and 
grinding steps, while not requiring the use of a solvent to induce 
cocrystallization, therefore qualifying as a green method of preparing 
cocrystals. Another limitation of grinding approaches to 
cocrystallization is that they are far less efficient and costlier 
compared to HME. As there are more processing steps involved and 
the process is not continuous, it will take longer to synthesize 
cocrystals, especially if manual grinding techniques are used. With 
HME the cocrystal components are continuously fed into the 
extruder, meaning the process is automatic and can be adjusted at 
short notice, something which cannot be done through grinding. This 
leads into another big drawback that it is difficult to scale up 
production using grinding methods. Due to the uniformity and 
continuous nature HME, it is relatively simple to scale up production, 
without editing too many processing parameters. With the addition 
of PAT technology, it is also possible to evaluate cocrystal quality in 
line and edit the temperature, screw speed and feed rate accordingly 
to accommodate scale up and address any issues immediately. 
Grinding techniques do not have this luxury. Cocrystals can only be 
characterised post production and if there are any issues present, 
then the process must be repeated from the start. All these issues 
equate to extra labour and processing time, with equal extra costs 75-
77, 108-113.  
 
Melt assisted grinding 
One technique which has been attempted in order to overcome 
solid state grindings pitfall of not involving a heating stage, while also 
not requiring the use of a solvent, is melt assisted grinding. In this 
technique, a physical mixture of the API and coformer will be heated 
until the melting point, then slowly cooled for cocrystallization to 
take place.  This method is similar to HME, in regards to the fact the 
constituents are heated together to achieve cocrystallization, but 
advantage HME holds over melting method is additional shear force 
and increased mixing. To demonstrate this method, as a means of 
cocrystallization with reduced melting temperatures Liu et al 111 
synthesized Carbamazepine-Nicotinamide cocrystals and compared 
the results to the same cocrystals produced via HME. To achieve the 
melting, the two base components were placed on a hot plate and 
ŚĞĂƚĞĚĂƚ ? ? ?ȗĂŶĚƚŚĞŶĐŽŽůĞĚƐůŽǁůǇĂƚĂŵďŝĞŶƚĐŽŶĚŝƚŝŽŶƐ ?dŚĞ
cocrystals were then crushed via mortar and pestle and passed 
through an 80-mesh sieve. The aim of the study was to produce 
Carbamazepine-nicotinamide cocrystals at low temperatures to 
avoid thermal degradation and in this regards the melting assisted 
cocrystallization method was successful as pure and stable cocrystal 
were produced. The HME produced cocrystals showed better 
dissolution properties. In another example Rahman et al 24, utilized 
melting assisted grinding to produce Carbamazepine-nicotinamide 
cocrystals. This was achieved by melting the base products on a 
paraffin oil bath at 140°C for 10 min and then cooled at room 
temperature. The cocrystals then were powdered by a mortar and 
pestle and passed through 60 mesh sieve. Though cocrystals were 
produced, analysis by SEM showed the cocrystals to be irregularly 
shaped, likely due to the crushing process following cooling. DSC 
analysis also showed that the cocrystals produced by this method 
contained some amorphous material in the batch. This method is a 
limited approach when compared to other techniques as it was 
shown to reduced quality cocrystals and there is also the inherent 
issue with the scale up using this method 24, 111.  HME is a continuous 
process, where the bulk products can be constantly fed through, into 
the extruder with the products being heated through the barrel. This 
is not possible with melt, assisted grinding as all components must 
be loaded onto the hot plate/ heating bath prior to the processes 
commencement. There are also added production steps, in HME the 
heating and grinding steps both take place in the extruder barrel, 
whereas these are two separate steps using melt method. They must 
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first be heated, cooled and then crushed, meaning HME is far more 
efficient.  
 
Regulatory perspectives of pharmaceutical cocrystals 
This article has demonstrated cocrystals pharmaceutical potential in 
drug development, so the next logical step would be gaining 
regulatory approval, to standardize how the growing drug types can 
be brought to market. However, there have been a number of issues 
preventing this. Over the last decade, as interest in cocrystal 
development had been growing, there have been a number of 
compositions of matter patents acknowledged for cocrystals. This 
has been on the basis that the cocrystals in question display the 
primary criteria for issuing a patent. These are the cocrystal is of a 
new molecular composition (not similar to the molecular structure 
ŽĨŽƚŚĞƌĚƌƵŐƐ ? ?ƚŚĞƌĞŝƐĂĚĞŐƌĞĞŽĨ ?ŶŽŶ- ŽďǀŝŽƵƐŶĞƐƐ ?ƚŚĂƚŵĞĂŶƐ
the physiochemical properties of the cocrystals are not easily 
predicted, and the new cocrystal must offer an advantage over the 
single component drug. This means that the new cocrystal must have 
certain enhanced properties which give it an edge over the bulk 
substance. This is done so that one drug development company 
cannot release a structurally different, but essentially analogous in 
function. Allowing this would allow the new substance to directly 
compete with the single component drug 126. 
The FDA released guidelines for the pharmaceutical industry in 
2011 pertaining to the patenting of cocrystals. Within these 
ŐƵŝĚĞůŝŶĞƐ ĐŽĐƌǇƐƚĂůƐ ǁĞƌĞ ĐůĂƐƐĞĚ ĂƐ ĂŶ  ?W/ ĞǆĐŝƉŝĞŶƚ ? ŵŽůĞĐƵůĂƌ
complex, a drug product intermediate and not a new API. This 
presented a problem for cocrystal development as an intermediate 
in drug development is not afforded the same benefits as a new API. 
In the document the FDA does not rank cocrystals in the same league 
as salts and polymorphs. The FDA required that a further two criteria 
be met before product approval would be granted, which were that 
API and excipient must completely dissociate prior to reaching the 
pharmacologically active site and also that he API and excipient are 
in neutral states and do not interact by ionic bonds.  
A perspective article was published as a response to this FDA ruling 
127. This article argued that the only difference between a crystalline 
salt and a cocrystal lies merely in the transfer of a proton from one 
component to the other, which is dependent on temperature 12, 127. 
Due to the fact that many drugs on the market are considered by 
many to be cocrystals, pharmaceutical companies lobbied the FDA 
with the opinion that cocrystals should be treated as salts, if not 
awarded their own subclass. Two examples of these are Depakote®, 
which contains sodium valproate Wvalproic acid and Caffeine citrate 
128, 129.  
In contrast to the FDAs position on the regulatory status of 
cocrystals; in 2015, the European Medicines Agency (EMA) released 
a reflection paper on summarising their position on the use of 
cocrystals of API in medicine 130. The paper states that the FDA 
believes cocrystals to be  ?ŚŽŵŽŐĞŶŽƵƐ  ?ƐŝŶŐůĞ ƉŚĂƐĞ ? ĐƌǇƐƚĂůůŝŶĞ
structures made up of two or more components in a definite 
stoichiometric ratio where the arrangement in the crystal lattice is 
not based on ionic bonds (as with salts) ? ?The paper concludes that 
cocrystallization is a viable alternative to salt formation and a 
method of achieving more solid state matter with unique properties 
130. The EMA state that as cocrystals and salts share a number of 
conceptual similarities, they should undergo similar principals of 
documentation as salts [81]. Although the FDA and EMA currently 
occupy very different viewpoints on the subject of the regulation of 
pharmaceutical cocrystals, the fact that both agencies have released 
guidelines for the industry to follow demonstrates the growing 
interest in the use of pharmaceutical cocrystals as potential 
marketable drugs.  
 
Future developments and remaining challenges  
As previously stated, one of the biggest limitations to the growth of 
cocrystals in the pharmaceutical industry is their current 
classification under regulatory guidelines. This is most prevalent in 
the United States, as while cocrystals are classified as an API 
excipient, there is little monetary gain cocrystal production. This is 
due to the fact that new cocrystal products are difficult to patent. 
Other challenges, which need to be addressed, include the stability 
of cocrystals in the presence of excipients, which is currently a 
relatively unexplored area. There are also the issues pertaining to the 
scale up, which currently make cocrystals an unattractive option to 
industry due to the fact mass production which is difficult.  
Despite this, research into cocrystals continues to grow and as 
more drug products that are based on cocrystal research hit the 
market, it can only be expected for pharmaceutical cocrystals to gain 
a stronger grip in drug development. The recently published 
reflection paper by the EMA states that cocrystals will be granted the 
status of new active substance if their efficacy and safety is proved 
130. The recent phase II success of tramadol and celecoxib co-crystals, 
a drug-drug cocrystal is a further sign that cocrystal development is 
advancing. In a 2014 article Blagden et al 132 cited current physical 
screening techniques as one of the key barriers in preventing 
cocrystal utilization due to the fact it is difficult to automate a high 
throughput screening technique. Blagden et al postulated that 
advancements in computational screening approaches would see 
further utilization of cocrystals as pharmaceutical products 132. 
Recently developed software by the Cambridge Crystallographic 
Data Centre (CCDC) such as Cambridge Structural Database (CSD)-
materials and CSD discovery provides software tools to assist in the 
intra-molecular interactions within the crystal lattice and in the 
discovery of new crystal forms respectively 133. dŚĞƐĞĂĚǀĂŶĐĞŵĞŶƚƐ ? 
along with improvements in scoring systems for cocrystal prediction 
134 ĂŶĚ ĂĚǀĂŶĐĞŵĞŶƚ ?Ɛ ŝŶ ŚǇĚƌŽŐĞŶ ďŽŶĚŝŶŐ ƌĞƐĞĂƌĐŚ ƐŚŽƵůĚ ŚĞůƉ
ĨĂĐŝůŝƚĂƚĞĂĚǀĂŶĐĞŵĞŶƚ ?ƐŝŶĐŽŵƉƵƚĂƚŝŽŶĂůŵŽĚĞůůŝŶŐ135.  
As has been previously explained in this article, HME 
demonstrates great potential to combat the issue related to the 
scale-up of cocrystallization and has already been demonstrated too 
do so 102, 114. In a recent paper, Boksa et al 113 successfully developed 
a method of polymer-assisted cocrystallization using HME to produce 
high quality cocrystals. This was achieved by embedding the 
cocrystals in 20 % soluplus. This method is solvent free, scalable and 
was shown to be amenable to continuous manufacturing, making it 
an area of great interest for future research. A similar method was 
employed by Basa et al using a polymer assisted grinding technique 
to synthesise caffeine-citric acid cocrystals. Six different alongside 
poly(ethylene glycol) polymers were used in this study and the 
results were compared to liquid assisted grinding methods. The 
results showed that polymer-assisted grinding compared favourably 
to the liquid assisted methods, whilst also eradicating the risk of 
unwanted solvent formation 136.  
ARTICLE Journal Name 
12 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
Other potential areas for further research in cocrystallization via 
HME relate to the use of potential PAT monitoring systems which 
have been utilized in other elements of HME production and could 
be used for cocrystals. For example, Saerens et al has successfully 
utilized Raman spectroscopy as an in-line monitoring tool for in HME 
for the extrusion of drug-polymer mixtures. In this case in-line Raman 
monitoring allowed for the influence of changes in the die pressure 
to be monitored. This can be translated to cocrystal research and can 
be used to assess the impact of temperature and screw 
configurations 137. Treffer et al has implemented in-line image based 
particle size analyses tools in HME, in order to monitor the particle 
properties of extruded pellets. This could potentially be incorporated 
in cocrystal extrusion to examine the effect of process parameters on 
cocrystal particle size and surface properties 138.  
 
Conclusions  
Research in pharmaceutical cocrystals will continue to grow as 
coformer-screening strategies become more simplified. Industrial 
interest in pharmaceutical cocrystals will continue to grow due to the 
enhanced pharmaceutical benefits they exhibit and because of the 
decreased drug development time it should take cocrystals to reach 
the market, due to aspects such as toxicology already being known. 
Recent advances in cocrystal engineering involve virtual 
computational screening while solid-state approaches for cocrystal 
synthesis appear to be attractive compared to solvent crystallization.  
HME is now widely recognized as a viable method to create 
pharmaceutical cocrystals due to the fact it is continuous, solvent-
free, cost efficient offers reduced production times, has fewer 
processing steps and quality assurance can be easily monitored. 
Nevertheless, there are several hurdles to overcome before 
pharmaceutical cocrystals are commercially fully exploited. 
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